Mónica S. Montesinos
Research Subjects
Mónica S. Montesinos has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Sandra Breuils-Bonnet
Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.).
2 shared publicationsAdrian S. Ray
Morphic Therapeutic, Waltham, United States
1 shared publication- Adrian S. Ray
Gilead Sciences, Inc., Foster City, California, USA
1 shared publication - Alice Bourgeois
Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.).
1 shared publication Andrew Mcteague
Morphic Therapeutic, Waltham, United States
1 shared publication- Andréanne Pelletier
Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Center, Quebec City, QC, Canada (S.-E.L., Y.G., T.Y., T.S., M.M., C.R., M.S., S.B.-B., A.B., C.T., A.P., R.E.K., S.M., K.Y., F.P., S.P., O.B., S.B.).
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 22 April 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (16) , 1162-1183
Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical Studies
BACKGROUND: Pulmonary arterial hypertension (PAH) is characterized by obliterative vascular remodeling of the small pulmonary arteries (PAs) and progressive increase in pulmonary vascular resistance leading to right ventricular failure. Although several drugs are approved for the treatment of PAH, mortality rates remain high. Accumulating evidence supports a pathological function of integrins in vessel remodeling, which are gaining renewed interest as drug targets. However, their role in PAH remains largely unexplored. METHODS: The expression of the RGD (arginylglycylaspartic acid)–binding integrin α5β1 was assessed in PAs, PA smooth muscle cells, and PA endothelial cells from patients with PAH and controls using NanoString, immunoblotting, and Mesoscale Discovery assays. RNA sequencing was conducted to identify gene networks regulated by α5β1 inhibition in PAH PA smooth muscle cells. The therapeutic efficacy of α5β1 inhibition was evaluated using a novel small molecule inhibitor and selective neutralizing antibodies in Sugen/hypoxia and monocrotaline rat models, with validation by an external contract research organization. Comparisons were made against standard-of-care therapies (ie, macitentan, tadalafil) and sotatercept and efficacy was assessed using echocardiographic, hemodynamic, and histological assessments. Ex vivo studies using human precision-cut lung slices were performed to further assess the effects of α5β1 inhibition on pulmonary vascular remodeling. RESULTS: We found that the arginine-glycine-aspartate RGD-binding integrin α5β1 is upregulated in PA endothelial cells and PA smooth muscle cells from patients with PAH and remodeled PAs from animal models. Blockade of the integrin α5β1 or depletion of the α5 subunit downregulated FOXM1 (forkhead box protein M1)–regulated gene networks, resulting in mitotic defects and inhibition of the pro-proliferative and apoptosis-resistant phenotype of PAH cells. We demonstrated that α5β1 integrin blockade safely attenuates pulmonary vascular remodeling and improves hemodynamics and right ventricular function and matched or exceeded the efficacy of standard of care and sotatercept in multiple preclinical models. Ex vivo studies further validated its potential in reversing advanced remodeling in human precision-cut lung slices. CONCLUSIONS: These findings establish α5β1 integrin as a pivotal driver of PAH pathology and we propose its inhibition as a novel, safe, and effective therapeutic strategy for PAH.
- 22 April 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (16) , 1162-1183
Top Cited PapersOpen AccessExploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical Studies
BACKGROUND: Pulmonary arterial hypertension (PAH) is characterized by obliterative vascular remodeling of the small pulmonary arteries (PAs) and progressive increase in pulmonary vascular resistance leading to right ventricular failure. Although several drugs are approved for the treatment of PAH, mortality rates remain high. Accumulating evidence supports a pathological function of integrins in vessel remodeling, which are gaining renewed interest as drug targets. However, their role in PAH remains largely unexplored. METHODS: The expression of the RGD (arginylglycylaspartic acid)–binding integrin α5β1 was assessed in PAs, PA smooth muscle cells, and PA endothelial cells from patients with PAH and controls using NanoString, immunoblotting, and Mesoscale Discovery assays. RNA sequencing was conducted to identify gene networks regulated by α5β1 inhibition in PAH PA smooth muscle cells. The therapeutic efficacy of α5β1 inhibition was evaluated using a novel small molecule inhibitor and selective neutralizing antibodies in Sugen/hypoxia and monocrotaline rat models, with validation by an external contract research organization. Comparisons were made against standard-of-care therapies (ie, macitentan, tadalafil) and sotatercept and efficacy was assessed using echocardiographic, hemodynamic, and histological assessments. Ex vivo studies using human precision-cut lung slices were performed to further assess the effects of α5β1 inhibition on pulmonary vascular remodeling. RESULTS: We found that the arginine-glycine-aspartate RGD-binding integrin α5β1 is upregulated in PA endothelial cells and PA smooth muscle cells from patients with PAH and remodeled PAs from animal models. Blockade of the integrin α5β1 or depletion of the α5 subunit downregulated FOXM1 (forkhead box protein M1)–regulated gene networks, resulting in mitotic defects and inhibition of the pro-proliferative and apoptosis-resistant phenotype of PAH cells. We demonstrated that α5β1 integrin blockade safely attenuates pulmonary vascular remodeling and improves hemodynamics and right ventricular function and matched or exceeded the efficacy of standard of care and sotatercept in multiple preclinical models. Ex vivo studies further validated its potential in reversing advanced remodeling in human precision-cut lung slices. CONCLUSIONS: These findings establish α5β1 integrin as a pivotal driver of PAH pathology and we propose its inhibition as a novel, safe, and effective therapeutic strategy for PAH.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA1619
Identification of integrin a5b1 inhibition as a potentially disease-modifying approach for the treatment of pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is characterized by pathogenic remodeling of the distal arteries arising from pulmonary arterial smooth muscle cell (PASMC) hyperplasia, pulmonary arterial endothelial cell (PAEC) dysfunction, and increased deposition of extracellular matrix (ECM). Given the central role of the ECM in the restructuring of vasculature, we investigated the potential to therapeutically target a5b1, a fibronectin-binding integrin implicated in cell proliferation and angiogenesis, for PAH. Immunohistochemical analysis of lungs from PAH patients revealed increased fibronectin and a5b1 expression in distal pulmonary arteries. To assess the function of a5b1, we have developed potent, orally bioavailable, small molecule inhibitors (SMi) and monoclonal antibodies (mAb) targeting a5b1. Selective inhibition of a5b1 in cultured PASMC modulated multiple pathways involved in cell cycle regulation at a transcriptional and post-transcriptional level and blocked cellular proliferation. Human precision cut lung slices (PCLS) treated with a5b1 inhibitors decreased expression of pathways involved in ECM deposition and decreased levels of smooth muscle cell markers. Finally, a5b1 inhibition with either a SMi or mAb significantly improved cardiac and vascular function in the rat Sugen/hypoxia PAH model by reducing pulmonary arterial wall thickness, right ventricular hypertrophy, and fibrosis. These data highlight a hitherto unappreciated role for a5b1 in the pathogenesis of PAH and support the potential for a5b1 inhibition as a disease-modifying therapeutic strategy for the management of PAH.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA1619
Identification of integrin a5b1 inhibition as a potentially disease-modifying approach for the treatment of pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is characterized by pathogenic remodeling of the distal arteries arising from pulmonary arterial smooth muscle cell (PASMC) hyperplasia, pulmonary arterial endothelial cell (PAEC) dysfunction, and increased deposition of extracellular matrix (ECM). Given the central role of the ECM in the restructuring of vasculature, we investigated the potential to therapeutically target a5b1, a fibronectin-binding integrin implicated in cell proliferation and angiogenesis, for PAH. Immunohistochemical analysis of lungs from PAH patients revealed increased fibronectin and a5b1 expression in distal pulmonary arteries. To assess the function of a5b1, we have developed potent, orally bioavailable, small molecule inhibitors (SMi) and monoclonal antibodies (mAb) targeting a5b1. Selective inhibition of a5b1 in cultured PASMC modulated multiple pathways involved in cell cycle regulation at a transcriptional and post-transcriptional level and blocked cellular proliferation. Human precision cut lung slices (PCLS) treated with a5b1 inhibitors decreased expression of pathways involved in ECM deposition and decreased levels of smooth muscle cell markers. Finally, a5b1 inhibition with either a SMi or mAb significantly improved cardiac and vascular function in the rat Sugen/hypoxia PAH model by reducing pulmonary arterial wall thickness, right ventricular hypertrophy, and fibrosis. These data highlight a hitherto unappreciated role for a5b1 in the pathogenesis of PAH and support the potential for a5b1 inhibition as a disease-modifying therapeutic strategy for the management of PAH.